<i>C</i>. <i>muridarum</i> respiratory infection induces CCR2 expression on lung tissue and immune cells. by Shuaini Yang (20670608)

Subjects:

Pathological changes in lung tissue of mice exposed to continuous inhalation of CS. by Yue He (385239)

Subjects:

Improved Accuracy and Reliability in Untargeted Analysis with LC-ESI-QTOF/MS¹ by Ensemble Averaging by Guillaume Laurent Erny (21000926)

Subjects:

Improved Accuracy and Reliability in Untargeted Analysis with LC-ESI-QTOF/MS¹ by Ensemble Averaging by Guillaume Laurent Erny (21000926)

Subjects:

Descriptive statistics of alcohol consumption in G7 countries (in litres/capita). by Luis Alberiko Gil-Alana (14659817)

Subjects:

Estimates of the differencing parameter, d, in Eq (1). by Luis Alberiko Gil-Alana (14659817)

Subjects:

Estimates of the differencing parameter, d, in Eq (1). by Luis Alberiko Gil-Alana (14659817)

Subjects:

Estimated coefficients based on the selected model in Table 4. by Luis Alberiko Gil-Alana (14659817)

Subjects:

Estimated coefficients based on the selected model in Table 3. by Luis Alberiko Gil-Alana (14659817)

Subjects:

CCR2 deficiency upregulates IL-4, IL-5, and Th2 transcription factors during <i>C</i>. <i>muridarum</i> infection. by Shuaini Yang (20670608)

Subjects:

CCR2 deficiency elevates <i>C</i>. <i>muridarum</i>-induced Th17-type immune response. by Shuaini Yang (20670608)

Subjects:

CCR2 deficiency attenuates the infiltration of myeloid cells and diminishes the numbers and activation of T cells following <i>C</i>. <i>muridarum</i> respiratory infection. by Shuaini Yang (20670608)

Subjects:

Th1 differentiation and IFN-γ secretion are impaired in <i>ccr2</i>^-/- mice during <i>C</i>. <i>muridarum</i> infection. by Shuaini Yang (20670608)

Subjects:

Reduced resistance and exacerbated lung inflammation in <i>ccr2</i>^-/- mice with <i>C</i>. <i>muridarum</i> respiratory infection. by Shuaini Yang (20670608)

Subjects:

Root mean square fluctuations of the wild-type (green line) and mutant (H5Q) (purple line) proteins of AKR1C3 (complexed with the ligand NADPH). by Md. Akeruzzaman Shaon (21511929)

Subjects:

Changes in connectivity of the mPFC among responders and non-responders. by Karel Joineau (21799908)

Subjects:

Data supporting this article. by Karel Joineau (21799908)

Subjects:

CONSORT diagram showing the flow of participants through each stage of the DOREPAR randomized trial for the main outcome (change of VAS). by Karel Joineau (21799908)

Subjects:

Demographic and clinical data at baseline. by Karel Joineau (21799908)

Subjects:

Changes in clinical variables. by Karel Joineau (21799908)

Subjects: